Growth stocks are a central component of any well-rounded portfolio. However, growth stocks are also inherently risky, necessitating that investors take extra caution prior to buying shares of any pure-play capital appreciation vehicle. 

Which growth equities sport favorable risk-to-reward profiles right now? While there are plenty of candidates to choose from in this volatile market, Ginkgo Bioworks (NYSE: DNA) and Harmony Biosciences (NASDAQ: HRMY) arguably stand out as two of the most attractive at current levels. Here's why risk-tolerant investors with an eye toward market-beating gains may want to load up on these two undervalued healthcare stocks in the fourth quarter. 

Image source: Getty Images.

Continue reading

Source Fool.com